Three efficacy endpoints were tested for noninferiority : ( 1 ) primary composite endpoint at 48-72 hours ( cessation of spreading or reduction in lesion size , absence of fever , and no rescue antibiotic ) ; ( 2 ) investigator-assessed clinical cure 7-14 days after end of treatment ; and ( 3 ) 20 % reduction in lesion area at 48-72 hours .